{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:01:33Z","timestamp":1791648093048,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite recent improvements in diagnostic and therapeutic strategies, gastric cancer (GC) continues to be a major contributor to global cancer fatalities, resulting in suboptimal patient prognosis overall. Cuproptosis, defined as a regulated death mode initiated by intracellular copper overload, has not been comprehensively examined in the context of the tumor immune microenvironment or its prognostic relevance in stomach adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive transcriptomic analyses of TCGA and GEO cohorts were performed to identify cuproptosis-related molecular subtypes and to develop a prognostic risk model based on cuproptosis-associated genes. Correlations between the risk score and features of the TIME were thoroughly evaluated. RT-qPCR was conducted in 14 paired gastric tumor and adjacent normal tissues to validate the expression of key prognostic genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three distinct cuproptosis-associated molecular subtypes were identified in STAD. A five-gene prognostic signature\u2014\n                      <jats:italic>PEG10, RPL39L, MMP11, SYNPO2,<\/jats:italic>\n                      and\n                      <jats:italic>KRT17<\/jats:italic>\n                      \u2014was established, which showed strong associations with overall survival and multiple immunological indicators, including immune cell infiltration, MSI, TMB, immune checkpoint expression, and HLA profiles. Subsequently, a nomogram provided enhanced individualized survival prediction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The identified cuproptosis-related gene signature is associated with the immunological heterogeneity of gastric cancer. Together, these results point to previously unrecognized links between cuproptosis and antitumor immunity, may provide insights for refining immunotherapeutic strategies in gastric cancer. Continued experimental investigation will be necessary to unravel how cuproptosis contributes to gastric cancer development and to validate its association with immune regulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1746613","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:34:45Z","timestamp":1770615285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cuproptosis-related gene signatures define immune subtypes and predict prognosis in gastric cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhe","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences","place":["Zhengzhou, China"]},{"name":"State Key Laboratory of Metabolic Dysregulation and the Prevention and Treatment of Esophageal Cancer","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingtong","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anyang District Hospital","place":["Anyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences","place":["Zhengzhou, China"]},{"name":"State Key Laboratory of Metabolic Dysregulation and the Prevention and Treatment of Esophageal Cancer","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]},{"name":"Tianjian Laboratory for Advanced Biomedical Sciences","place":["Zhengzhou, China"]},{"name":"State Key Laboratory of Metabolic Dysregulation and the Prevention and Treatment of Esophageal Cancer","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1039\/c6mt00202a","article-title":"Defining the human copper proteome and analysis of its expression variation in cancers","volume":"9","author":"Blockhuys","year":"2017","journal-title":"Metallomics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1002\/imt2.190","article-title":"Clinical features and molecular landscape of cuproptosis signature-related molecular subtype in gastric cancer","volume":"3","author":"Chong","year":"2024","journal-title":"Imeta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","article-title":"Connecting copper and cancer: from transition metal signalling to metalloplasia","volume":"22","author":"Ge","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-025-02192-0","article-title":"The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer","volume":"10","author":"Guo","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","article-title":"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment","volume":"35","author":"Gupte","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.4049\/jimmunol.1700786","article-title":"Copper regulates maturation and expression of an MITF:Tryptase axis in mast cells","volume":"199","author":"Hu Frisk","year":"2017","journal-title":"J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41416-020-01053-7","article-title":"Immunophenotype based on inflammatory cells, PD-1\/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer","volume":"123","author":"Junttila","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1096\/fj.13-231571","article-title":"Prostate cancer cell migration induced by myopodin isoforms is associated with formation of morphologically and biochemically distinct actin networks","volume":"27","author":"Kai","year":"2013","journal-title":"Faseb J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","article-title":"Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer","volume":"10","author":"Li","year":"2019","journal-title":"Cell Death Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.2147\/cmar.S243129","article-title":"KRT17 functions as a tumor promoter and regulates proliferation, migration and invasion in pancreatic cancer via mTOR\/S6k1 pathway","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2025.02.12","article-title":"Different strategies for cancer treatment: targeting cancer cells or their neighbors?","volume":"37","author":"Liu","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","article-title":"Technical and biological biases in bulk transcriptomic data mining for cancer research","volume":"16","author":"Liu","year":"2025","journal-title":"J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms241210201","article-title":"Different roles of apoptosis and autophagy in the development of human colorectal cancer","volume":"24","author":"Orlandi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.7150\/ijms.98007","article-title":"Matrix metalloproteinase 11 promotes migration and invasion of colorectal cancer by elevating slug protein","volume":"21","author":"Pan","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3390\/ijms22073418","article-title":"Gastric cancer: advances in carcinogenesis research and new therapeutic strategies","volume":"22","author":"Seeneevassen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1073\/pnas.1817473116","article-title":"ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis","volume":"116","author":"Shanbhag","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19105","article-title":"A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins","volume":"5","author":"Sung","year":"2016","journal-title":"Elife"},{"key":"B25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1158\/1078-0432.Ccr-18-3016","article-title":"Immunotherapeutic blockade of macrophage Clever-1 reactivates the CD8(+) T-cell response against immunosuppressive tumors","volume":"25","author":"Viitala","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1158\/0008-5472.Can-20-0471","article-title":"Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion","volume":"80","author":"Voli","year":"2020","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.ai.2019.11.007","article-title":"Metalloimmunology: the metal ion-controlled immunity","volume":"145","author":"Wang","year":"2020","journal-title":"Adv. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41423-022-00866-1","article-title":"Cuproptosis: a new form of programmed cell death","volume":"19","author":"Wang","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"111846","DOI":"10.1016\/j.intimp.2024.111846","article-title":"Deciphering JAK\/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions","volume":"131","author":"Wang","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cancergen.2024.09.002","article-title":"Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer","author":"Wang","year":"","journal-title":"Cancer Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4161\/rna.27427","article-title":"RPL39L is an example of a recently evolved ribosomal protein paralog that shows highly specific tissue expression patterns and is upregulated in ESCs and HCC tumors","volume":"11","author":"Wong","year":"2014","journal-title":"RNA Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3892\/or.2023.8673","article-title":"SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy","volume":"51","author":"Ye","year":"2024","journal-title":"Oncol. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e002467","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12935-023-03013-6","article-title":"Synaptopodin-2: a potential tumor suppressor","volume":"23","author":"Zheng","year":"2023","journal-title":"Cancer Cell Int."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1746613\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:59:23Z","timestamp":1771927163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1746613\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":38,"alternative-id":["10.3389\/fmolb.2026.1746613"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1746613","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1746613"}}